Placentas from streptozotocin-diabetic rats have previously been shown to be morphologically and biochemically immature when compared with those of control rats. The binding of epidermal growth factor (EGF) to plasma membranes prepared from placentas of control and streptozotocin-diabetic fetuses has been characterized on days 17 and 21 of gestation. Results from competitive binding data analyzed by Scatchard analysis indicate the presence of a single class of receptors on day 17 (KD = 5.4 X 10-10) and the appearance of a second class of binding sites for`zI-EGF by day 21 (KD= 3.5 X 10'9) in membranes from control fetuses. Placental membranes from diabetic fetuses show decreased specific binding (-30%) on both days and the absence of a second class of binding sites on day 21 of gestation. Results from a radioreceptor assay indicate that the quantity of EGF in the serum of fetuses removed from control rats on day 21 is twofold greater than the quantity in sermm offetuses from diabetic rats. These data reveal a developmental increase in EGF-binding sites in the placenta of normal near-term fetal rats, largely because of the appearance of a second class of binding sites with a lower affinity for WGF. The failure (or delay) of this second class to develop in the diabetic may be important for the control of maturation and growth of this tissue.
Introduction
In humans, the diabetic state during pregnancy leads to fetal hyperglycemia and hyperinsulinism which results in placentomegaly and fetal macrosomia (1, 2) . Infants of diabetic mothers also exhibit a delay in lung maturation and a greatly increased risk for the development of hyaline membrane disease (3) . In previous studies utilizing fetuses of streptozotocin-diabetic rats (4, 5) , we reported that hyperglycemia per se was associated with increased placental growth and delayed maturation during late gestation. DNA levels reach a maximum on day 16 in placentas from control rats whereas placentas from diabetic rats continue to increase in DNA content until days [18] [19] and are morphologically immature when compared with control tissues. These fetuses, which are hyperglycemic but are not hyperinsulinemic, also exhibit delayed morphologic and biochemical maturation of lung.
To define the mechanisms by which the fetal diabetic state and the concomitant hyperglycemia influence growth and maturation ofthe placenta, we have investigated the binding ofepidermal growth factor (EGF)' to surface receptors ofmembranes prepared from placentas of control and streptozotocin-diabetic fetuses at different gestational ages. EGF binds to cell surface receptors which are autophosphorylated by a protein kinase on the internal domain ofthe receptor (6, 7) . EGF has been shown in many cell types to stimulate an array of biochemical and morphologic changes including cell proliferation, organ differentiation, and transport of small molecules.
Adamson and Warshaw (8) provided evidence that the receptor for EGF could be "down-regulated" in vivo by EGF. Later studies involving the binding characteristics of EGF to placental membranes during stages of gestation indicated that receptor number is increased and binding affinity is decreased as gestation nears term (9) . It was suggested that EGF may stimulate proliferation in immature tissues and differentiation as the tissues mature. Lai and Guyda (10) provided data from in vitro experiments that specific binding ofEGF to placental membranes increases during gestation to reach a maximum at term. The authors proposed that EG1 may be involved in the regulation of fetal growth and development. The data reported here show striking changes in EGF binding to placental membranes of diabetic fetuses and are supportive of the hypothesis that an interaction between glucose supply and receptor binding exists and is important for placental growth and maturation.
Methods
Animals. Nonpregnant adult virgin female Sprague-Dawley rats (Holtzmann 250-300 g) were injected intravenously with 50 mgfkg of streptozotocin (Upjohn Co., Kalamazoo, MI), a specific pancreatic beta-cell cytotoxin, dissolved in 5 mM citrate buffer, pH 4.5. Control rats received an equivalent volume of buffer. Serum glucose levels were determined to confirm the diabetic state of each animal, and only those animals with glucose values > 300 mg% were considered to be diabetic. Females were then placed in cages with stud male rats and tested for the presence of sperm each morning. The morning that sperm were detected was designated day 0 of pregnancy. Approximately 60-70% of attempted matings were successful.
Preparation ofcrude cell membranefraction. Animals were killed by decapitation on days 17 and 21. The uterine horns were rapidly removed and placed on ice. Placentas were removed, weighed, and processed immediately. All procedures were conducted at 0-4C. Plasma membranes were prepared by a modification of the method of Morishige et al. (i 1). Tissue was homogenized in 10 vol of0.3 M sucrose in 0.25 M Tris-HCl, pH 7.6, containing 10 mM MgCl2 using a Polytron (Brinkmann Instrument Co., Westbury, NY) and the homogenate was centrifuged at 800 g for 10 minutes. The supernatant was centrifuged at 20,000 g for 20 min and the pellet suspended in 20 vol of 0.25 M Tris-HCl buffer, pH 7.6, containing 10 mM MgCl2 (TM buffer). The pellet was twice resuspended in buffer and centrifuged at 20,000 g for 10 min. The final pellet was resuspended in buffer and adjusted to yield 3 mg of protein/ml. Protein was assayed according to method ofLowry et al. (12) . This fraction was then used in the binding assays.
S'-Nucleotidase assay. The procedure employed for assay of 5'-nucleotidase is based on measuring the nucleoside produced by the hydrolytic action of the enzyme on the nucleotide substrate. A kit purchased from Sigma Diagnostics (St. Louis, MO) was used to measure the nucleoside employing an enzyme kinetic method reported by Arkesteijn (13) . The rate of NAD formation, as determined by the decrease in absorbance at 340 nm, utilizing a Gilford 2600 spectrophotometer (Gilford Instrument Laboratories, Inc., Oberlin, OH), is directly proportional to the rate of adenosine formation and therefore, 5'-nucleotidase activity.
'25I-EGF-binding assay. by centrifugation in a Beckman microfuge (Beckman Instruments, Inc., Fullerton, CA) at 10,000 g for 10 min. Tubes were counted for 10 min in a Packard 51 10 gamma counter (Packard Instrument Co., Downers Grove, IL). EGF receptor number and affinity were determined by Scatchard analysis (14) ofcompetitive binding assay data which were evaluated by means of a computer program called LiGAND (15) .
Degradation experiment. To determine that EGF degradation did not occur during the time course of binding assays, 1251I-EGF (2 X 10' cpm per assay tube) was incubated in the absence (control) and presence (experimental) ofplacental membrane as described above. Five tubes of each were removed at 15-min time intervals from 0-90 min and immediately centrifuged. The supernatant was removed and protein precipitated by 10% trichloroacetic acid (TCA) as described by other authors (1, 10). Rebinding experiment. Magnesium chloride (MgCI2) was used as a dissociating agent to remove bound EGF from the membranes by a procedure modified from Kelly et al. (16) . MgCl2 was dissolved in TM buffer to give concentrations 1, 2, 3, and 4 M and kept at room temperature until use. The binding assay was repeated as described above. After counting, the pellets from the binding assay were resuspended in 0.5 ml of MgCl2, vortexed, and incubated for 5 min. Tubes were centrifuged in a Beckman microfuge at 10,000 gfor 10 min. The supernatant was aspirated and the pellets were counted. The pellets were resuspended in 0.10 ml of binding buffer and binding assay repeated as described above.
Radioreceptor assay. The amount of EGF present in amniotic fluid and fetal serum was measured by radioreceptor assay. Human placental membranes were isolated according to a modification of the method of Hock and Hollenburg (17) . All procedures were performed at 0-40C. Fresh term human placenta (150 g) was chopped, rinsed, and homogenized in 10 volumes of 0.250 M sucrose, 0.025 M Tris-HCI, pH 7.4. The suspension was filtered through cheesecloth and centrifuged for 10 min at 600 g. The supernatant was centrifuged at 10,000 g for 30 min, adjusted to contain 0.1 M NaCl and 0.2 mM MgSO4, and centrifuged for 40 min at 48,000 g. The pellet was washed with 50 mM Tris-HCl, pH 7.6, centrifuged for 30 min at 48,000g, suspended in 15 ml Dulbecco's phosphate-buffered saline (Gibco, Grand Island, NY), 0.1 M Hepes (Sigma Chemical Co.), 0.1% BSA (Sigma Chemical Co., Fraction V), pH 7.4, to yield a membrane fraction containing -10-15 mg/ml protein, and frozen in 100 Al aliquots at -80'C. Human placental membranes (5 Mg of membrane protein), 40,000-45,000 dpm 125I-EGF, and varying amounts ofcold EGF (0-1,000 ng/tube) or test sample in a final volume of 300 Ml were incubated in Dulbecco's PBS buffer at room temperature for 1 h with shaking. The reaction was terminated by the addition of 1 ml of ice-cold incubation buffer, and filtered through Whatman GF/C filters, (Whatman, Inc., Clifton, NJ) using the Millipore 3025 Sampling Manifold (Millipore Corp., Bedford, MA). The assay tube was rinsed once with 1 ml ofice-cold buffer, and the filter was rinsed three additional times with ice-cold buffer. The filter was counted in a Packard 5110 Gamma scintillation counter. A displacement curve was constructed by plotting bound '25I-EGF vs. log EGF concentration. EGF activity present in the sample was estimated by the amount of '23I-EGF displaced.
Results
As shown in Fig. 1 , maximal binding of 1251I-EGF to placental membranes was achieved in 60-90 min at both the lowest and highest concentration of EGF used to obtain Scatchard plots. Equilibrium was reached by 40 min in those samples containing 1 ,ug of EGF per tube (representing nonspecific binding). Under the conditions of the assay, specific binding of '25I-EGF was shown to increase linearly with increasing placental membrane protein (Fig. 2) . All assays were conducted with 300 ,g of membrane protein per/tube in a total volume of 250 Ml. There was no statistical difference in percent recovery of 5'-nucleotidase in membrane fractions isolated from control and diabetic placentas. This indicates that the relative purity of membranes was similar in the two groups. Data shown in Fig. 3 Fig. 6 represents competitive binding data of 125I-EGF to placental membranes isolated from control and diabetic rats on day 17 ofgestation. The data yield linear Scatchard plots on day 17 and the lines of best fit were found by linear regression analysis to be compatible with a single class of receptors with high-affinity binding site (KD = 5.4 X 10-10 and 6.0 X 1O-0io, respectively).
Receptor number in placental membranes from diabetic fetuses on day 17 is significantly (P > 0.05) reduced from a mean of 2.9 X 108 in the control to 1.8 X 108 in the diabetic. Data of placental membranes isolated from fetuses of controls on day 21 ofgestation result in a curvilinear plot and is consistent with the model for two binding sites (Fig. 7) . The plot can be resolved Fig. 4 . Results from radioreceptor assays for EGF are shown in Table I. Samples ofamniotic fluid obtained on day 17 ofgestation indicate -0.4 ng of EGF/ml of fluid in both the control and the diabetic. By day 21, the levels of EGF had increased in both groups to -0.9 ng/ml. On day 21 the level of EGF in serum from fetuses ofcontrols was -10.0 ng/ml. Serum from fetuses ofdiabetic rats contained 4.6 ng/ml, a figure that represents less than half the value found in controls. Fetuses removed on day 17 do not yield sufficient amounts of serum for the assay.
Discussion
Placentas from diabetic rats have been characterized by means ofmorphologic and biochemical indices as immature compared with those of control rats although the placentas continue to grow and have increased DNA content during the final stages ofgestation. The immature state of placentas from diabetic animals is characterized by the presence of large numbers of glycogen-distended cells in the junctional zone (5) . The interhemal membrane is significantly thicker in the diabetic placenta and large accumulations of lipid droplets are prominent. Previous studies have documented increased levels ofglycogen in diabetic placentas and a delay in the appearance ofactive phosphorylase which likely regulates glycogenolysis (4). Placentas from diabetic animals at term (22 d) were histologically similar to 18-d control placentas. The amount of DNA in these placentas increases until the 19th day ofgestation whereas maximum levels ofDNA occur by days 16-17 in placentas from control rats (4) . It can be speculated that the decrease in EGF binding in the diabetic placenta is related to continued cell proliferation rather than maturation.
A less mature placenta with thickened interhemal membranes may affect fetal growth by increasing the diffusion distance between maternal and fetal circulations (5) and may partially account for the limitation of fetal growth observed in this model.
In the present study we describe marked alteration in binding (18, 19) . TGF-0 purified from human placenta interferes with receptor downregulation (20) . To examine the possibility that one or more of these peptides is present in either the control placenta or the diabetic placenta and may contribute to the observed binding differences, the plasma membranes from control and diabetic rats were mixed equally (based on protein content (Fig. 6 ). Placental membranes from day 21 diabetics show similar binding characteristics to those seen on day 17 (Fig. 7) . By day 21, competitive EGF binding to membranes from controls result in a curvilinear plot suggestive ofthe appearance ofa second class ofreceptors (KD= 3.5 X 10-9). The curvilinearity ofthis plot makes it difficult to precisely define receptor numbers for the two apparent sites. Data on day 21 of gestation however indicate a 30% reduction of specific binding to membranes from placentas of diabetic rats when compared with values for controls (Fig. 3) . It is tempting to speculate that the receptor with higher affinity is present at an early stage of development when cell growth is the primary activity and as the levels of EGF rise in control rats near term, EGF induces the synthesis ofits own receptor in a manner similar to that described by Earp et al. (22) . In normal placenta, the appearance and occupancy of a second class of binding sites with a decreased affinity for EGF would be associated with a decrease in cell proliferation and an increase in maturation. Smith and Talamantes (23) recently reported a major increase in numbers of a loweraffinity binding site on mouse placental membranes toward the end of gestation. Their results differ from ours in that they observed curvilinear plots of EGF binding in mouse placental membranes for all gestational ages. This may relate to species differences. Lai and Guyda (10) have reported that 125I-EGF binding to membranes from human placental cell cultures also exhibited curvilinearity which they interpreted as receptor heterogenicity. This is consistent with our observations.
Excessive substrate supply as exists in the diabetic state may regulate EGF receptor number and affinity and result in continued cell division and growth at a time when the placenta normally undergoes hypertrophy and maturation. The precise mechanism by which the EGF receptor interacts with other hormones and available substrates to regulate developmental events in the placenta is unknown. Such differences as we report here in binding of EGF to placental membranes in the diabetic state may provide important clues concerning differential EGF influences on growth and maturation. In the placenta of a diabetic rat, continued cell proliferation and decreased binding of EGF may be due to masking ofthe EGF receptor in the membrane, alterations in receptor cycling, or alterations in the synthesis, processing, or insertion into the plasma membrane of the new receptor.
These possibilities are currently being investigated.
